S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Public ClinicalTrials.gov record NCT06188702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP
Study identification
- NCT ID
- NCT06188702
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Enrollment
- 342 participants
Conditions and interventions
Conditions
Interventions
- S095035 Drug
- TNG462 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2024
- Primary completion
- Oct 30, 2031
- Completion
- Oct 30, 2031
- Last update posted
- Apr 2, 2026
2024 – 2031
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles | Los Angeles | California | 90095 | Not yet recruiting |
| University of California, San Francisco (Ucsf) School of Medicine | San Francisco | California | 94143 | Not yet recruiting |
| Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute | Lake Mary | Florida | 32746 | Terminated |
| Community Health Network | Indianapolis | Indiana | 46250 | Recruiting |
| Dana Farber Cancer Institue | Boston | Massachusetts | 02215 | Not yet recruiting |
| Duke University School of Medicine | Durham | North Carolina | 27710 | Not yet recruiting |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| NEXT Oncology | Austin | Texas | 78758 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06188702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06188702 live on ClinicalTrials.gov.